Claim: Autism has now been included among the known side effects of the  DTaP (Diphtheria, Tetanus, and acellular Pertussis) vaccine.
Verdict: REFUTES

Retrieved passages:
title: Pertussis vaccine
text: Tetanus, acellular Pertussis), with the main difference that the adult version contains smaller amounts of the diphtheria and pertussis components—this is indicated in the name by the use of lower-case "d" and "p" for the adult vaccine. The lower-case "a" in each vaccine indicates that the pertussis component is acellular, or cell-free, which reduces the incidence of side effects. The pertussis component of the original DPT vaccine accounted for most of the minor local and systemic side effects in many vaccinated infants (such as mild fever or soreness at the injection site). The newer acellular vaccine, known as DTaP, has

title: Childhood immunizations in the United States
text: three diseases; Diphtheria, Pertussis and Tetanus. The DTaP vaccine is given as a 5-shot series at 2, 4, and 6 months, the fourth between 12 and 15 months, and the last between 4–6 years. A booster is recommended to be given between 11 and 12 years of age and is called Tdap. Some potential side effects of DTaP are; mild: uncommon: severe: It is important to note that these severe side effects are so rare that it is hard to correlate the vaccine and these symptoms. Potential side effects of Tdap; Diphtheria was once a major cause of illness and

title: DPT vaccine
text: In 2009, the journal "Pediatrics" concluded the largest risk among unvaccinated children was not the contraction of side effects, but rather the disease that the vaccination aims to protect against. DTP was licensed in 1949. DTaP and Tdap are both combined vaccines against diphtheria, tetanus, and pertussis. The difference is in the dosage, with the upper case letters meaning higher quantity. DTaP (also DTPa and TDaP) is a combined vaccine against diphtheria, tetanus, and pertussis, in which the pertussis component is acellular. This is in contrast to whole-cell, inactivated DTP (aka DTwP). The acellular vaccine uses selected antigens of the

title: Diphtheria vaccine
text: (1-in 12,500 doses), and hypotonic-hyporesponsive episodes ( 1-in 1,750 doses). Side effects of DTaP vaccines are similar but less frequent. Tetanus toxoid containing vaccines (Td, DT, DTP and DTaP) may cause brachial neuritis at a rate of 1 out of every 100,000 to 200,000 doses. The World Health Organization has recommended vaccination against diphtheria since 1974. The first dose is recommended at six weeks of age with two additional doses four weeks apart, after receiving these three doses about 95% of people are immune. Three further doses are recommended during childhood. Booster doses every ten years are no longer recommended.

title: Tetanus vaccine
text: acellular form of the pertussis vaccine because of safety concerns. Half of those who received the DTP vaccine had redness, swelling, and pain around the injection site which convinced researchers to find a replacement vaccine. Two new vaccines were launched in 1992. These combined tetanus and diphtheria with acellular pertussis (TDaP or DTaP) which could be given to adolescents and adults (as opposed to previously when the vaccine was only given to children). Tetanus vaccine Tetanus vaccine, also known as tetanus toxoid (TT), is an inactive vaccine used to prevent tetanus. During childhood five doses are recommended, with a sixth

title: Pertussis vaccine
text: pertussis" bacteria. Until the beginning of the 1990s it was used as a part of the DTwP vaccine for the immunization of children. It, however, contained pertussis endotoxin (surface lipooligosaccharide) and produced side effects. New acellular pertussis vaccines were developed in the 1980s, which included only a few selected pertussis antigens (toxins and adhesins). Acellular vaccines are less likely to provoke side effects. They became a part of DTaP vaccines for children. In 2005, two new vaccine products were licensed for use in adolescents and adults that combine the tetanus and diphtheria toxoids with acellular pertussis vaccine. These (Tdap) vaccines

title: National Vaccine Information Center
text: autism. The CDC now recommends the newer acellular pertussis vaccines (DTaP and Tdap), and whole cell pertussis vaccines are no longer used in the U.S. due to adverse effects unrelated to autism. In the early 1980s, the organization joined with the American Academy of Pediatrics to draft the original legislation for the National Childhood Vaccine Injury Act of 1986, which created a federal vaccine injury compensation program, mandated that doctors give parents vaccine benefit and risk information, and required the recording and reporting of vaccine injuries and deaths (see Vaccine Adverse Event Reporting System). The organization changed its name to

title: Pertussis vaccine
text: have had a neurologic event after a previous dose not be vaccinated until after treatment is initiated and the condition stabilized. Only the acellular vaccine is used in the US. As of 2018 there are four acellular DTaP/Tdap vaccines licensed for use in USA: Infanrix and Daptacel – for children, Boostrix and Adacel – for adolescents and adults. Pertussis vaccine is usually administered as a component of the diphtheria-tetanus-pertussis (DTP/DTwP, DTaP and Tdap) vaccines. There are several types of diphtheria-tetanus-pertussis vaccines. The first vaccine against pertussis was developed in the 1930s by pediatrician Leila Denmark. It included whole-cell killed "Bordetella

title: DPT vaccine
text: pertussis pathogen to induce immunity. Because it uses fewer antigens than the whole cell vaccines, it is considered safer, but it is also more expensive. Recent research suggests that the DTP vaccine is more effective than DTaP in conferring immunity; this is because DTaP's narrower antigen base is less effective against current pathogen strains. Also dTpa, is a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) was licensed in the United States for use in adults and adolescents on June 10, 2005. The lower case "d" and "p" indicated smaller concentrations of diphtheria toxoids and pertussis antigens, and

title: Diphtheria vaccine
text: at the site of injection that lasts a few weeks. The vaccine is safe in both pregnancy and among those who have a poor immune function. The diphtheria vaccine is delivered in several combinations. Some combinations (Td and DT vaccines) include tetanus vaccine, others (known as DPT vaccine or DTaP vaccine depending on the pertussis antigen used) comes with the tetanus and pertussis vaccines, and still others include additional vaccines such as Hib vaccine, hepatitis B vaccine, or inactivated polio vaccine. The World Health Organization has recommended its use since 1974. About 84% of the world population is vaccinated. It

title: DPT vaccine
text: the patient's prior history of receiving Tdap. DPT vaccine DPT (also DTP and DTwP) is a class of combination vaccines against three infectious diseases in humans: diphtheria, pertussis (whooping cough), and tetanus. The vaccine components include diphtheria and tetanus toxoids and killed whole cells of the bacterium that causes pertussis (wP). DTaP and Tdap refer to similar combination vaccines in which the component "P" or "p" with lower case "a" is acellular. Also available are the DT and Td vaccines, which lack the pertussis component. In the United Kingdom, the Netherlands and France, the abbreviation DTP refers to a combination

title: Diphtheria vaccine
text: number of cases globally between 1980 and 2000. About 86% of the world population was vaccinated as of 2016. Severe side effects from diphtheria toxoid are rare. Pain may occur at the injection site. A bump may form at the site of injection that lasts a few weeks. The vaccine is safe during pregnancy and among those who have a poor immune function. DTP vaccines may cause additional adverse effects such as fever, irritability, drowsiness, loss of appetite, and, in 6-13% of vaccine recipients, vomiting. severe adverse effects of DTP vaccines include fever over 40.5C/104.9F (1-in 333 doses), febrile seizures

title: Tetanus vaccine
text: if not, immunizing them can prevent neonatal tetanus. The vaccine is very safe including during pregnancy and in those with HIV/AIDS. Redness and pain at the site of injection occur in between 25% and 85% of people. Fever, feeling tired, and minor muscles pains occur in less than 10% of people. Severe allergic reactions occur in less than one in 100,000 people. A number of vaccine combinations include the tetanus vaccine such as DTaP and Tdap which contain diphtheria, tetanus, and pertussis vaccine, and DT and Td which contain diphtheria and tetanus vaccine. DTaP and DT are given to children

title: Exotoxin
text: in multiple doses throughout childhood with adjuvants and boosters for long-term immunity. DPT vaccine protects against pertussis, tetanus and diphtheria infections, caused by the exotoxin-producing "Bordetella pertussis", "Clostridium tetani" and "Corynebacterium diphtheriae" respectively. Vaccination with the toxoids generates antibodies against the exotoxins, forming immunological memory as protection against subsequent infections. The DPT vaccination may cause adverse side effects, such as swelling, redness and fever, and is contraindicated in some populations. Effective vaccination schedules have reduced rates of mortality linked to pertussis, tetanus and diphtheria but formal controlled trials to test the efficacy of the vaccine have not been conducted. Additionally,

title: Vaccine
text: of diphtheria (D) and tetanus (T) toxoids and pertussis (P) vaccine. Lower-case "d" and "p" denote reduced doses of diphtheria and pertussis used in the adolescent/adult-formulations. The 'a' in DTaP and Tdap stands for 'acellular,' meaning that the pertussis component contains only a part of the pertussis organism." Another list of established vaccine abbreviations is at the CDC's page called "Vaccine Acronyms and Abbreviations", with abbreviations used on U.S. immunization records. The United States Adopted Name system has some conventions for the word order of vaccine names, placing head nouns first and adjectives postpositively. This is why the USAN for

title: Tetanus vaccine
text: completed with Td. The first vaccine is administered at infancy. The baby is injected with the DTaP vaccine which is 3 inactive toxins in one injection. DTaP protects against diphtheria, pertussis, and tetanus. This vaccine is safer than the previously used DTP. Another option for infants is DT, which is a vaccine that is a combination of diphtheria and tetanus vaccines. This is given as an alternative to infants who have conflicts with the DTaP vaccine. Quadrivalent, pentavalent, and hexavalent formulations contain DTaP with one or more of the additional vaccines: inactivated poliovirus vaccine (IPV), Haemophilus influenzae type b conjugate,

title: Thiomersal controversy
text: benefits than risks from thiomersal exposure with respect to developmental disorders. Because the Danish and UK studies involved only diphtheria-tetanus-pertussis (DTP) or diphtheria-tetanus (DT) vaccines, they are less relevant for the higher thiomersal exposure levels that occurred in the U.S. In North America, a Canadian study of 27,749 children in Quebec showed that thiomersal was unrelated to the increasing trend in pervasive developmental disorders (PDDs). In fact, the study noted that rates of PDDs were higher in the birth cohorts with no thiomersal when compared to those with medium or high levels of exposure. A study performed in the US

title: DPT vaccine
text: DPT vaccine DPT (also DTP and DTwP) is a class of combination vaccines against three infectious diseases in humans: diphtheria, pertussis (whooping cough), and tetanus. The vaccine components include diphtheria and tetanus toxoids and killed whole cells of the bacterium that causes pertussis (wP). DTaP and Tdap refer to similar combination vaccines in which the component "P" or "p" with lower case "a" is acellular. Also available are the DT and Td vaccines, which lack the pertussis component. In the United Kingdom, the Netherlands and France, the abbreviation DTP refers to a combination vaccine against diphtheria, tetanus, and poliomyelitis. In

title: Pertussis vaccine
text: in the US by the end of 1985. In response, Congress passed the National Childhood Vaccine Injury Act (NCVIA) in 1986, establishing a federal no-fault system to compensate victims of injury caused by recommended vaccines. Concerns about side effects led Sato to introduce an even safer acellular vaccine for Japan in 1981 that was approved in the US in 1992 for use in the combination DTaP vaccine. The acellular vaccine has a rate of adverse events similar to that of a Td vaccine (a tetanus-diphtheria vaccine containing no pertussis vaccine). Pertussis vaccine Pertussis vaccine is a vaccine that protects against

title: DPT vaccine
text: "a" in "ap" indicates that the pertussis toxoids are acellular. Two Tdap vaccines are available in the U.S. Adacel, manufactured by Sanofi Pasteur, is licensed for use in adults ages 11 to 64. Boostrix, manufactured by GlaxoSmithKline, is licensed for use in adolescents and adults ages 10 to 64. In January 2011, the U.S.'s Advisory Committee on Immunization Practices (ACIP) recommended Tdap's use in adults of all ages, including those age 65 and above. In October 2011, in an effort to reduce the burden of pertussis in infants, the ACIP recommended that unvaccinated pregnant women receive a dose of Tdap.